The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Official Title

The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors

Brief Summary

      The purpose of this study is to find out whether certain anti-HIV drugs (efavirenz [EFV] and
      nelfinavir [NFV]) affect the amount of certain fat-lowering drugs (atorvastatin, pravastatin,
      and simvastatin) in the blood.

      Protease inhibitors (PIs), a type of anti-HIV drug, are known to cause increased lipids
      (fats) in the blood of HIV-infected patients. EFV also is known to increase blood fats.
      HIV-infected patients who take PIs and/or EFV may need to take fat-lowering drugs to correct
      this problem. So it is important to look at possible drug interactions when these drugs are
      taken together. This study will see if taking EFV or NFV, a protease inhibitor, affects the
      blood level of simvastatin, atorvastatin, or pravastatin (all fat-lowering drugs). To obtain
      results more quickly, the study population will be healthy HIV-negative volunteers.
    

Detailed Description

      Abnormalities in lipid metabolism are a recognized side effect of protease inhibitor (PI)
      therapy in HIV-infected patients. EFV also is known to increase plasma cholesterol. In an
      attempt to normalize serum lipids in HIV-infected patients on PIs and/or EFV,
      Hydroxymethylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) may
      be prescribed. Therefore, it is important to study how PIs and EFV affect the PK of
      concurrently-administered statins. Many of the statins utilize the cytochrome P450 (CYP) 3A4
      enzyme for metabolism. In addition, atorvastatin and simvastatin have active metabolites,
      generated via CYP3A4, that contribute to the drugs' lipid-lowering activity and probably to
      their toxicity. Pravastatin is not metabolized by CYP3A4 but is inactivated by conjugation,
      non-CYP3A4-induced hydroxylation, and renal excretion. NFV, the most commonly used PI, is an
      inhibitor of CYP3A4 and an inducer of other CYPs and conjugative pathways. EFV is a mixed
      CYP3A4 inhibitor and inducer. This study examines the effect of NFV on the PK of pravastatin
      and the effect of EFV on the PK of simvastatin, atorvastatin, and pravastatin. As EFV with
      pravastatin is expected to be a common drug combination during the treatment of HIV
      infection, it should be explored further, even though drug interactions are not expected. To
      expedite this study, the study population is comprised of healthy control volunteers.

      Volunteers are assigned to 1 of 4 groups. Volunteers in Groups A, B, and C take a statin
      (simvastatin, atorvastatin, or pravastatin, respectively) on Days 0 to 3. After Day 3, the
      statin is stopped and EFV is begun. Volunteers take EFV until Day 14 and the statin and EFV
      together from Days 15 to 18. Volunteers in Group D take pravastatin on Days 0 to 3, NFV on
      Days 4 to 12, and pravastatin and NFV together on Days 13 to 16. Fasting lipid profiles are
      performed on Days 0, 4, 15, and 19 for Groups A, B, and C, and on Days 0, 3, 13, and 16 for
      Group D. PK sampling is performed on Days 3, 14, and 18 for Groups A, B, and C (requiring an
      overnight stay), and on Days 3 and 16 for Group D. Volunteers receive monetary compensation
      for participation in this study.
    

Study Phase

Phase 1

Study Type

Interventional




Condition

HIV Infections

Intervention

Pravastatin sodium


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

56




Eligibility Criteria

        Inclusion Criteria

        Volunteers may be eligible for this study if they:

          -  Are HIV-negative.

          -  Are 18 to 60 years old.

          -  Weigh at least 50 kg (110 lbs) and are within 30 percent of their ideal body weight.

          -  Cannot have children (have reached menopause [change of life] for at least 24 straight
             months or have had a hysterectomy), if female and enrolling to Group A, B, or C.

          -  Have a negative pregnancy test within 14 days before study entry and within 24 hours
             before starting the study drugs, if female, able to have children, and enrolling to
             Group D.

          -  Agree to avoid trying to become pregnant or causing someone to become pregnant. Agree
             not to donate sperm or participate in other fertilization procedures. If participating
             in sexual activity that could lead to pregnancy, the study volunteer and/or partner
             must use 2 reliable methods of birth control at the same time, while taking study
             drugs, and for 6 weeks after stopping the drugs. Male volunteers are allowed to be
             sexually active without the use of birth control if they have had a successful
             vasectomy or are sterile.

        Exclusion Criteria

        Volunteers will not be eligible for this study if they:

          -  Have or have had heart, kidney, blood, nerve, digestive, mental, hormonal, or immune
             system diseases. These include high blood pressure, blocked arteries, arthritis,
             diabetes, stomach or intestinal problems, depression, and past use of antidepressant
             drugs.

          -  Are pregnant or breast-feeding.

          -  Have used experimental, prescription, or over-the-counter drugs within 14 days before
             study entry, except for aspirin (ASA), acetaminophen (Tylenol), diphenhydramine
             (Benadryl), daily multivitamins, mineral supplements, birth control pills or implants,
             and hormone replacement therapy for women who have reached menopause.

          -  Are allergic to study drugs or their ingredients.

          -  Abuse drugs or alcohol.

          -  Have a medical condition that, in the opinion of the investigator, would interfere
             with their participation in the study.

          -  Have participated in any experimental drug study within 30 days before study entry.

          -  Are not able to keep their usual diet during the study or are unable to write down
             their food intake before the study visits.

          -  Have an abnormal urine test result, e.g., urinary tract infection, kidney disease, or
             kidney stones.
      

Gender

All

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

John Gerber, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00017758

Organization ID

ACTG A5108

Secondary IDs

AACTG A5108


Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)


Study Sponsor

John Gerber, Study Chair, 


Verification Date

February 2004